During the past decade, Regional Oncology Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 4 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Regional Oncology Center" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Byondis B.V." with 1 trials sponsored, "Center Trials & Treatment" with 1 trials sponsored, "Clovis Oncology, Inc." with 1 trials sponsored and "Galena Biopharma, Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Regional Oncology Center" #1 collaborator was "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "BioGene Pharmaceutical Inc." with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Frontier Science & Technology Research Foundation, Inc." with 1 trials as a collaborator and "Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Regional Oncology Center" are "Breast Cancer With Low to Intermediate HER2 Expression" (1 trials), "Breast Neoplasms" (1 trials), "Cytomegalovirus (CMV)" (1 trials), "Endometrial Cancer" (1 trials) and "Glioblastoma" (1 trials). Many other conditions were trialed in "Regional Oncology Center" in a lesser frequency.

Most popular intervention types in "Regional Oncology Center" are "Drug" (7 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Bendamustine" (1 trials), "CO-1.01" (1 trials), "Cyclophosphamide" (1 trials) and "Dose-dense Doxorubicin or dose-dense Epirubicin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Regional Oncology Center" are 7 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Regional Oncology Center". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Regional Oncology Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Regional Oncology Center, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Regional Oncology Center has several departments that took part in Clinical trials: "Irkutsk Regional Oncology Dispensary" - 13 trials